Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited announced the quotation of 788,786 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 1, 2025. This move reflects the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its financial standing and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines and vaccines. The company is known for its work in plasma-derived therapies, vaccines, and other specialty biopharmaceutical products, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 997,842
Technical Sentiment Signal: Sell
Current Market Cap: A$101.8B
See more data about CSL stock on TipRanks’ Stock Analysis page.